Peripheral Artery Disease

Three publications in JACC: Cardiovascular Interventions showed how intravascular lithotripsy may benefit patients with severely calcified lesions.

Endovascular intervention conferred less in-hospital mortality but more postprocedural complications compared with surgical revascularization in patients with peripheral artery disease due to chronic total occlusion, new data suggest.

In a new analysis of the COMPASS trial, rivaroxaban plus aspirin outperformed aspirin alone in overall and CV mortality among patients with chronic CAD or peripheral artery disease.

Patients with peripheral artery disease and HF have higher rates of CAD and elevated risk for adverse CV events and mortality compared with patients with PAD but no HF, researchers reported.

In the SAFE-PAD cohort study of patients with peripheral artery disease designed in part by the FDA, there was no difference in mortality between those treated with paclitaxel-coated devices and those treated with uncoated devices.

Rivaroxaban plus low-dose aspirin reduced incidence of total severe CV and other adverse events in patients with peripheral artery disease who had lower-extremity revascularization, according to new data from the VOYAGER PAD trial.

A strategy of directional atherectomy followed by drug-coated balloon treatment was beneficial in patients with long, calcified femoropopliteal lesions, according to 12-month results of the REALITY study.

In a head-to-head trial, a low-dose paclitaxel-coated balloon was noninferior to a higher-dose paclitaxel-coated balloon for treatment of patients with peripheral artery disease.

A helical stent to treat peripheral artery disease without extensive lesion preparation was safe and effective at 2 years in a real-world population with long and complex lesions, a speaker reported.

In a new meta-analysis covering more than 7,000 patients with peripheral artery disease, there was no association between paclitaxel-coated devices and all-cause mortality, researchers reported.